Your browser does not support iframes.
Your browser does not support iframes.
Your browser does not support iframes.
This is the new picture of hepatitis C’s E2 protein, which the
virus uses to infect liver cells, will aid in the design of a vaccine
against the disease. Credit: Christina Corbaci, The Scripps Research
Scientists at The Scripps Research Institute (TSRI) have determined
the most detailed picture yet of a crucial part of the hepatitis C
virus, which the virus uses to infect liver cells. The new data reveal
unexpected structural features of this protein and should greatly speed
efforts to make an effective hepatitis C vaccine.
The findings, which appear in the November 29, 2013 issue of the journal Science, focus on a protein known as E2 envelope glycoprotein.
Aneurin Bevan Health Board said that, as part of look back exercise
to find any patients who may have contracted the disease from the
worker, who is now retired, two further women had been identified.
exercise, which saw more than 3,300 patients being tested for the
virus, was launched in September after the health board became aware
that a former healthcare worker in obstetrics and gynaecology had been
diagnosed with hepatitis C and had unknowingly transmitted the virus to
two patients between May 1984 and July 2003.
Thousands of former
patients were written to and tested for the virus, and it has been
discovered that hepatitis C was transmitted from the former healthcare
worker to the further two women.
“Faldaprevir* has been studied with pegylated
interferon and ribavirin in a broad range of more than 3,300 patients
typical of those that doctors see in every day clinical practice.
Faldaprevir* has demonstrated strong efficacy and a robust safety
profile while also offering the convenience of once-daily dosing and no
food restrictions,” said Professor Klaus Dugi, Corporate Senior Vice
President Medicine at Boehringer Ingelheim. “The acceptance for
accelerated assessment by the EMA supports our position that if
approved, faldaprevir* will provide an important alternative to
currently available hepatitis C treatments.”
assessment status does not automatically lead to a positive opinion from
the Committee for Medicinal Products for Human Use (CHMP) or the
granting of a marketing authorization by the European Commission.1 If approved by the European Commission, faldaprevir* could be available for marketing in the EU in the second half of 2014.
EMA Marketing Authorisation Application is based on a comprehensive
clinical development programme for faldaprevir* with a particular focus
on the Phase III STARTVerso™ trial data, recently presented at the 64th
Annual Meeting of the American Association for the Study of Liver
Diseases (AASLD). These studies include data for faldaprevir* in:
For full results see the STARTVerso™ press release here.
Faldaprevir* is the foundation of
Boehringer Ingelheim’s hepatitis C treatment pipeline and is being
developed in combinations both with and without interferon. In addition
to the interferon-based faldaprevir* regimen that has been submitted for
marketing approval, Boehringer Ingelheim aims to deliver one of the
first interferon-free regimens for the treatment of hepatitis C
infection. The goal is to make an interferon-free future a reality for a
broad range of hepatitis C patients. Pivotal Phase III HCVerso® data
for the interferon-free regimen of faldaprevir*, deleobuvir* and
ribavirin will be available in 2014.
About Boehringer Ingelheim in hepatitis C
pioneering science, Boehringer Ingelheim is striving to find answers to
the pressing challenges still faced by the diverse population of
hepatitis C patients. The company’s comprehensively designed hepatitis C
clinical trial programme includes a broad range of patients including
those with the most challenging types of hepatitis C to cure that
clinicians see every day in clinical practice.
Ingelheim is developing faldaprevir*, an investigational second
generation protease inhibitor, in combinations both with and without
Interferon-based therapy with faldaprevir* has the
potential to improve cure rates with the added convenience of once-daily
dosing and no food restrictions. In clinical trials, faldaprevir* has
shown efficacy in a broad range of genotype-1a and 1b hepatitis C
patients. The Phase III STARTVerso™ trial programme, which includes
treatment-naïve, treatment-experienced and HIV co-infected patients with
hepatitis C virus, is nearly complete.
Deleobuvir* is a potent investigational
non-nucleoside NS5B polymerase inhibitor used in combination with
faldaprevir and ribavirin for the treatment of patients with genotype-1b
hepatitis C virus. The Phase III HCVerso® trials, investigating this
interferon-free regimen are well underway.
As part of Boehringer Ingelheim’s long-term
commitment to hepatitis C, the company is also evaluating other
combinations of investigational hepatitis C compounds that work in
different ways. Boehringer Ingelheim’s recent collaboration with
Presidio Pharmaceuticals, Inc. for a Phase II clinical study
investigating an interferon-free, all-oral, potentially ribavirin-free
combination is part of the company’s continued exploration to discover
and develop innovative options for the treatment of hepatitis C.
POWELL, Wyoming — Health officials are investigating an increase in
reported cases of the liver disease hepatitis C among young people in
Park County, with evidence suggesting needle sharing among intravenous
drug users might be to blame.
The probe came after 56 new reports of hepatitis C
infections were logged in the county in 2012 — a figure that exceeds the
state average and is about double the number of the year before, The
Powell Tribune reported (http://bit.ly/IdTgtX ) last week.
care providers at all levels of the health care system can help reduce
health disparities and prevent viral hepatitis by learning more about
the prevention, care, and treatment of this disease. This is one of the
goals of the Action Plan for the Prevention, Care and Treatment of Viral Hepatitis [PDF
673KB], to “Build a U.S. health-care workforce prepared to prevent and
diagnose viral hepatitis and provide care and treatment to infected
Medical providers who share information regarding risk for certain
diseases are one of the most powerful motivators for a patient to accept
an intervention or change behaviors. But providers must first have the
information needed to share with patients. Increasing the number of
providers who are knowledgeable about viral hepatitis testing, care, and
treatment is critical to maximizing the benefits afforded by viral
hepatitis testing and treatment options.
The Centers for Disease Control and Prevention (CDC) and the U.S. Department of Health and Human Services (HHS)
have collaborated with other federal agencies and universities to
create educational opportunities for health care providers to receive
training in this area of disease prevention and control.
The University of Washington in collaboration with the International
Antiviral Society-USA (IAS-USA) was funded by CDC to create a
self-study, interactive course for medical providers on Hepatitis C.
Features include a master bibliography, embedded video, and clinical
calculators. Free CME/CNE credit available.
The University of Washington – Seattle Prevention Training Center was
funded by CDC to develop a website that offers interactive case studies
covering topics related to prevention, management, and treatment of
viral hepatitis. Free CME/CNE credit available.
The University of Alabama at Birmingham – National Training Center
for Integrated Hepatitis, HIV/STD Prevention Services was funded by CDC
to develop a website dedicated to the provision of practice-focused
distance learning programs and training for frontline workers.
Medscape and CDC have worked together to provide the following educational opportunities:
The American Association for the Study of Liver Diseases (AASLD)
has launched an educational program providing practical strategies for
managing patients with hepatitis C. Five interactive modules, webinars,
and an experiential component address an overview of HCV, genotyping and
predictors of response, selecting patients, initiating treatment and
the first eight weeks, and managing side effects of therapy.
Registration is free, but required.
Broader use of these training resources by medical providers will
have a positive impact on our efforts to support viral hepatitis
testing, care, and treatment. To receive viral hepatitis updates from
CDC, including training opportunities, please sign up to receive email
communications through GovDelivery and follow CDC’s Division of Viral Hepatitis on Twitter @cdchep .
IPSWICH health services hand out 1000 syringes a day to drug addicts –
solely for the purpose of injecting illicit intravenous drugs.
A drug expert says the figure is an indication of the seriousness of
Ipswich’s heroin and speed problem, but health officials and the police
believe intravenous drug use is not on the rise.
West Moreton Hospital and Health Service dispenses the clean syringes
from Ipswich Health Plaza to reduce the spread of HIV and Hepatitis B